Local recurrence risk of esophageal squamous cell carcinoma due to intralesional damage during endoscopic submucosal dissection.
Endoscopic submucosal dissection
Esophageal squamous cell carcinoma
Pathology
Recurrence
Residual tumor
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
26
06
2023
received:
19
04
2023
accepted:
10
07
2023
medline:
23
10
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
It is unclear whether additional treatment should be considered given the recurrence risk after endoscopic submucosal dissection (ESD) for esophageal squamous cell carcinoma (ESCC) when the vertical margin is positive or unclear (VM1/VMX) due to intralesional damage. This study aimed to elucidate the local recurrence risk of ESCC caused by intralesional damage during ESD. Among consecutive patients with pT1a ESCCs initially treated by ESD at our institution between January 2006 and December 2018, ESCCs diagnosed as VM1/VMX were retrospectively reviewed. Exclusion criteria were piecemeal resection and any additional treatment after ESD. Intralesional damage included the following three types: a macroscopic hole inside the lesion, an incision from the lateral margin of the specimen into the lesion, and crushing injury or burn effect into the deepest area of the lesion without an obvious hole. The local recurrence rate after ESD was primarily analyzed. Of 1174 pT1a ESCCs initially treated using ESD, 22 lesions were histopathologically diagnosed as VM1/VMX due to intralesional damage (1.9%; 95% confidence interval [CI], 1.2-2.8%). At a median follow-up period of 60.0 (interquartile range, 15.0-84.0) months, no local recurrence was observed (0.0%; 95% CI, 0.0-13.3%) among 21 lesions finally evaluated. The impact of intralesional damage during ESD for ESCC on local recurrence might be negligible. Follow-up without additional treatment may be acceptable even if intralesional damage occurs and results in VM1/VMX after ESD for pT1a ESCCs.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
It is unclear whether additional treatment should be considered given the recurrence risk after endoscopic submucosal dissection (ESD) for esophageal squamous cell carcinoma (ESCC) when the vertical margin is positive or unclear (VM1/VMX) due to intralesional damage. This study aimed to elucidate the local recurrence risk of ESCC caused by intralesional damage during ESD.
METHODS
METHODS
Among consecutive patients with pT1a ESCCs initially treated by ESD at our institution between January 2006 and December 2018, ESCCs diagnosed as VM1/VMX were retrospectively reviewed. Exclusion criteria were piecemeal resection and any additional treatment after ESD. Intralesional damage included the following three types: a macroscopic hole inside the lesion, an incision from the lateral margin of the specimen into the lesion, and crushing injury or burn effect into the deepest area of the lesion without an obvious hole. The local recurrence rate after ESD was primarily analyzed.
RESULTS
RESULTS
Of 1174 pT1a ESCCs initially treated using ESD, 22 lesions were histopathologically diagnosed as VM1/VMX due to intralesional damage (1.9%; 95% confidence interval [CI], 1.2-2.8%). At a median follow-up period of 60.0 (interquartile range, 15.0-84.0) months, no local recurrence was observed (0.0%; 95% CI, 0.0-13.3%) among 21 lesions finally evaluated.
CONCLUSIONS
CONCLUSIONS
The impact of intralesional damage during ESD for ESCC on local recurrence might be negligible. Follow-up without additional treatment may be acceptable even if intralesional damage occurs and results in VM1/VMX after ESD for pT1a ESCCs.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1802-1807Informations de copyright
© 2023 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Katada C, Muto M, Momma K et al. Clinical outcome after endoscopic mucosal resection for esophageal squamous cell carcinoma invading the muscularis mucosae--a multicenter retrospective cohort study. Endoscopy 2007; 39: 779-783.
Ishihara R, Tanaka H, Iishi H et al. Long-term outcome of esophageal mucosal squamous cell carcinoma without lymphovascular involvement after endoscopic resection. Cancer 2008; 112: 2166-2172.
Ishihara R, Iishi H, Uedo N et al. Comparison of EMR and endoscopic submucosal dissection for en bloc resection of early esophageal cancers in Japan. Gastrointest. Endosc. 2008; 68: 1066-1072.
Oyama T, Tomori A, Hotta K, Morita S, Kominato K, Tanaka M, Miyata Y. Endoscopic submucosal dissection of early esophageal cancer. Clin. Gastroenterol. Hepatol. 2005; 3: S67-S70.
Fujishiro M, Yahagi N, Kakushima N et al. Endoscopic submucosal dissection of esophageal squamous cell neoplasms. Clin. Gastroenterol. Hepatol. 2006; 4: 688-694.
Takahashi H, Arimura Y, Masao H et al. Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest. Endosc. 2010; 72: 255-64.e2.
Japan Esophageal Society. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus 2017; 14: 1-36.
Nakahira H, Kanesaka T, Uedo N et al. Risk of recurrence when cutting into intramucosal (pT1a) cancer from the cutting-plane side during gastric endoscopic submucosal dissection. Endoscopy 2020; 52: 833-838.
Hayasaka J, Kikuchi D, Nomura K et al. Recurrence rate of intramucosal gastric cancer with positive vertical margin due to lesion damage during endoscopic submucosal dissection. Acta Gastroenterol. Belg. 2021; 84: 289-294.
Koike Y, Hirasawa D, Fujita N et al. Usefulness of the thread-traction method in esophageal endoscopic submucosal dissection: randomized controlled trial. Dig. Endosc. 2015; 27: 303-309.
Yoshida M, Takizawa K, Nonaka S et al. Conventional versus traction-assisted endoscopic submucosal dissection for large esophageal cancers: a multicenter, randomized controlled trial (with video). Gastrointest. Endosc. 2020; 91: 55-65.e2.
Kuwabara H, Abe S, Nonaka S, Suzuki H, Yoshinaga S, Oda I, Saito Y. Clinical feasibility of endoscopic submucosal dissection with minimum lateral margin of superficial esophageal squamous cell carcinoma. Endosc Int Open 2019; 7: E396-E402.
Oda I, Shimizu Y, Yoshio T et al. Long-term outcome of endoscopic resection for intramucosal esophageal squamous cell cancer: a secondary analysis of the Japan Esophageal Cohort study. Endoscopy 2020; 52: 967-975.
Yeh JH, Huang RY, Lee CT et al. Long-term outcomes of endoscopic submucosal dissection and comparison to surgery for superficial esophageal squamous cancer: a systematic review and meta-analysis. Therap. Adv. Gastroenterol. 2020; 13: 1756284820964316.
Ishihara R, Iishi H, Takeuchi Y et al. Local recurrence of large squamous-cell carcinoma of the esophagus after endoscopic resection. Gastrointest. Endosc. 2008; 67: 799-804.
Minashi K, Nihei K, Mizusawa J et al. Efficacy of endoscopic resection and selective chemoradiotherapy for stage I esophageal squamous cell carcinoma. Gastroenterology 2019; 157: 382-90.e3.
Nakajo K, Abe S, Oda I et al. Impact of the Charlson comorbidity Index on the treatment strategy and survival in elderly patients after non-curative endoscopic submucosal dissection for esophageal squamous cell carcinoma: a multicenter retrospective study. J. Gastroenterol. 2019; 54: 871-880.
Hatta W, Koike T, Takahashi S et al. Risk of metastatic recurrence after endoscopic resection for esophageal squamous cell carcinoma invading into the muscularis mucosa or submucosa: a multicenter retrospective study. J. Gastroenterol. 2021; 56: 620-632.
Katada C, Yokoyama T, Hirasawa D et al. Curative management after endoscopic resection for esophageal squamous cell carcinoma invading muscularis mucosa or shallow submucosal layer - multicenter real-world survey in Japan. Am. J. Gastroenterol. 2022. https://doi.org/10.14309/ajg.0000000000002106
Nakajo K, Yoda Y, Hori K et al. Technical feasibility of endoscopic submucosal dissection for local failure after chemoradiotherapy or radiotherapy for esophageal squamous cell carcinoma. Gastrointest. Endosc. 2018; 88: 637-646.
Ishihara R, Arima M, Iizuka T et al. Endoscopic submucosal dissection/endoscopic mucosal resection guidelines for esophageal cancer. Dig. Endosc. 2020; 32: 452-493.